# AbbVie Moat

Status: published. Policy: company-analysis-1.

AbbVie has a narrow moat grounded in product-specific intellectual property and commercially successful therapies. Demonstrated market-share gains and portfolio growth support a current advantage, while Humira's realized erosion after loss of exclusivity shows its limits. Pricing power is mixed across products and constrained by government pricing and reimbursement negotiations. The passages do not establish exceptional durability, strong switching costs or a structural cost advantage.

## intangible_assets

Product-specific patent rights and successful differentiated therapies support a current competitive advantage. Rinvoq, Botox Therapeutic, Ubrelvy and Qulipta gained market share, while portfolio growth offset substantial Humira erosion. Patent enforcement demonstrates existing rights and challenges, not assured litigation success.

Durability: Narrow and dependent on individual products, enforceable rights and continued commercial innovation. Regulatory and biologics development requirements create entry hurdles, but the supplied passages lack patent-expiration schedules and comparative efficacy evidence needed to establish a long protection horizon.

Risks: Humira revenue fell sharply following biosimilar entry. Imbruvica experienced unfavorable pricing and lower demand. Government-set prices can constrain economics before patent expiry, and proposed generic products challenge migraine-treatment patents. Pipeline programs and announced acquisitions represent potential replenishment rather than established replacement advantages.

Invalidation: The thesis would weaken materially if sustained market-share losses across the growing therapies coincided with patent defeats or generic entry, and replacement-product growth ceased to offset exclusivity losses. Persistent portfolio revenue contraction alongside deteriorating realized pricing would contradict the demonstrated replenishment advantage.

Competitors: Aurobindo Pharma U.S.A., Inc., Apotex Inc.
- [https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm) · 2026-02-20
- [https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm) · 2026-08-03
- [https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm](https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm) · 2026-03-23

[JSON](https://beanvest.com/stock/abbv/moat.json)